Rimegepant is Now Available in Hong Kong, the First Market in Asia, for Migraine Management
- Written by PR Newswire
HONG KONG, Sept. 29, 2023 /PRNewswire/ -- Pfizer announced the availability of Rimegepant in Hong Kong, the first market in Asia, a calcitonin gene-related peptide (CGRP) receptor antagonist for migraine management.[1],[2] There are approximately 12.5% of people living with migraine in Hong Kong[3] and it is one of the leading causes of disability...
